COGT (Cogent Biosciences) EPS without NRI: $-2.20 (TTM As of Mar. 2026)


COGT Cogent Biosciences Inc COGT
25 GF Score
Price $38.48
! 4 Warning Signs
View Full Analysis

What is Cogent Biosciences EPS without NRI?

Cogent Biosciences COGT -0.57% 25 EPS without NRI is $-2.20 as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,171 Biotechnology companies, Cogent Biosciences ranks worse than 78.14% on this metric.

Cogent Biosciences's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.53. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cogent Biosciences's EPS without NRI or its related term are showing as below:

COGT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -84.1   Med: -3.95   Max: 46.4
Current: -6.7

COGT's 3-Year EPS without NRI Growth Rate is ranked worse than
78.14% of 1171 companies
in the Biotechnology industry
Industry Median: 16.8 vs COGT: -6.70

Cogent Biosciences's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.53. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.20.

Cogent Biosciences's EPS (Basic) for the three months ended in Mar. 2026 was $-0.53. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.20.


Cogent Biosciences  (NAS:COGT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cogent Biosciences EPS without NRI Related Terms


Cogent Biosciences EPS without NRI Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences EPS without NRI Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.87 -1.73 -1.94 -1.94 -2.10

Cogent Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.53 -0.50 -0.64 -0.53

COGT vs SRRK, CGON, LGND: EPS without NRI Comparison

For the Biotechnology subindustry, Cogent Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogent Biosciences PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's PE Ratio without NRI falls into.


COGT
25GF Score
Cogent Biosciences Inc COGT
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-2.20 mean?
Cogent Biosciences (COGT) has a EPS without NRI of $-2.20 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cogent Biosciences and its competitors. According to the industry distribution chart, Cogent Biosciences ranks #915 out of 1171 companies in the Biotechnology industry, placing it in the top 78.1%.
Is Cogent Biosciences' EPS without NRI too high?
Cogent Biosciences' current EPS without NRI is $-2.20. Based on the distribution chart, Cogent Biosciences ranks #915 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' EPS without NRI compare to SRRK and CGON?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #915 out of 1171 companies for EPS without NRI. This places Cogent Biosciences in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cogent Biosciences and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current EPS without NRI is $-2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current EPS without NRI of $-2.20. The current EPS without NRI is $-2.20. Cogent Biosciences' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current EPS without NRI is $-2.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score

Get the complete analysis for COGT

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.48
Price